Reviewer’s report

Title: Additive effects of blood glucose lowering drugs, statins and renin-angiotensin system blockers on all-site cancer risk in patients with type 2 diabetes

Version: 3 Date: 11 March 2014

Reviewer: Zachary Bloomgarden

Reviewer’s report:

I do not think that the authors have addressed the following comment in my original review: "This statistical issue, which has been termed “allocation bias,” is the most striking potential limiting factor in the interpretation of the report, and is subtly but importantly different from bias by indication, which indeed should be demonstrable to some extent from the covariates used in the analysis."

I think acknowledgement of the potential that such bias might exist is important to the credibility of the report.

Quality of written English: Acceptable

Statistical review: Yes, and I have assessed the statistics in my report.

Declaration of competing interests:

I have received payments for consultations and lectures from BMS, Astra-Zeneca, Jansen, Merck, Novartis, Borhinger Ingelheim, NovoNordisk, Santarus, and am a stockholder in Novartis, Baxter International, CVS Caremark, Roche Holdings, and St Jude Medical, all of which entities might have some financial interest in the medications taken by individuals with diabetes, and hence in the subject of this report. Moreover, I have a large clinical practice taking care patients with diabetes, so the logic of declarations of competing interests would in this regard also be considered relevant to my "interests."